Replicel RCH-01 Hair Regeneration
RepliCel Life Sciences is one of the few research companies that has generated a lot of interests in our community. It is a Canadian based company, incorporated in British Columbia and currently listed on the TSX Venture Exchange in Canada, stock symbol RP.
Similar to Histogen, RepliCel is another company that focuses on the research and development of regenerative medicine based on autologous cell therapies that treat common conditions linked deficiency or defects in healthy cells.
RCH-01 Hair Regeneration
RCH-01 is one of RepliCel's product pipelines that has been followed closely by our community.
According to RepliCel, RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. The dermal sheath cup cells are extracted by means of a small punch biopsy taken from the back of the patient's scalp. The harvested cells will then be cultured or multiplied and then reintroduced into the balding areas of the patient's scalp.
At the time when this article is published, RepliCel has already formed an important partnership with Shiseido which now has an exclusive license for RCH-01 in Japan, China and South Korea. It is very likely that RCH-01 will be available in certain Asian countries before it hits the US or European markets.
Below is a video that explains very well RCH-01's treatment protocol and concept. Video is created by RepliCel and included here via Youtube share embedd code.
Read forum discussions about RepliCel: